 SENS stock has already achieved a lot, and if its its 180-day Eversense diabetes monitoring product gets approval Senseonics should shift out of neutral. The post Senseonics Stock Has a Huge Catalyst you Shouldnt Sleep On appeared first on InvestorPlace. 